biOasis Technologies Ord Shs V.BTI

Primary Symbol: V.BTI.H Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Bottom Line: xB3 never in a stronger position

<< Previous

Bullboard Posts

Next >>

Comment by ronrydellon Dec 16, 2022 9:42pm

110 Views

Post# 35177221

RE:RE:RE:Bottom Line: xB3 never in a stronger position

Agreed! I wonder who the appropriate people are paying off prophetoffactz to write his posts....1. So much for the number of the posts...2. So much for the content of the posts. A carefully manipulation of information to influence the reception of Tuesday webinar leading to the February 28, 2023 vote at the AGM.

When will we get to the "trillion number" since it's getting so commonplace in the news these days...

LOL! Interesting strategy for the lame minds who may buy into this!

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading